FDA clears second-generation Monarch eTNS System for treating pediatric ADHD

The FDA has cleared NeuroSigma’s second-generation Monarch eTNS System for treatment of pediatric ADHD, the company announced in a press release.
The Monarch 2.0 device is approximately one-third the size of the first-generation Monarch eTNS System and includes a high-resolution color LCD screen and optimized user interface. It is indicated as a monotherapy for patients aged 7 to 12 years who are not currently taking prescription ADHD medications, according to the release.
“In 2023, NeuroSigma executed on the first part of its commercial rollout by introducing patients, families and

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart